While prostate cancer is commonly treated first with surgery or radiation, sometimes a different strategy is appropriate.
An approach called targeted therapies may be the treatment of choice when cancer recurs or when a patient's tumor can be controlled at an earlier stage by manipulating its growth signals.
Targeted therapies are possible because clinical researchers have identified several good molecular targets in the cancer cell. Some therapies are FDA-approved, and others are still being evaluated in clinical trials. Because cancer frequently involves alterations in multiple signaling pathways, clinical trials often test combinations of targeted therapies along with standard treatments.